These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26842912)

  • 21. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
    Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
    Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-gamma increases monocyte PD-L1 but does not diminish T-cell activation.
    Galbraith NJ; Walker SP; Gardner SA; Bishop C; Galandiuk S; Polk HC
    Cell Immunol; 2020 Nov; 357():104197. PubMed ID: 32891037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
    Prima V; Kaliberova LN; Kaliberov S; Curiel DT; Kusmartsev S
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1117-1122. PubMed ID: 28096371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis.
    Oliveira Silva KL; Marin Chiku V; Luvizotto Venturin G; Correa Leal AA; de Almeida BF; De Rezende Eugenio F; Dos Santos PSP; Fabrino Machado G; De Lima VMF
    Comp Immunol Microbiol Infect Dis; 2019 Feb; 62():76-87. PubMed ID: 30711051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
    Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
    Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.
    Tanaka T; Kutomi G; Kajiwara T; Kukita K; Kochin V; Kanaseki T; Tsukahara T; Hirohashi Y; Torigoe T; Okamoto Y; Hirata K; Sato N; Tamura Y
    Oncotarget; 2017 Apr; 8(15):24706-24718. PubMed ID: 28160557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression is increased in a subset of basal type breast cancer cells.
    Soliman H; Khalil F; Antonia S
    PLoS One; 2014; 9(2):e88557. PubMed ID: 24551119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
    Choi JW; Withers SS; Chang H; Spanier JA; De La Trinidad VL; Panesar H; Fife BT; Sciammas R; Sparger EE; Moore PF; Kent MS; Rebhun RB; McSorley SJ
    PLoS One; 2020; 15(7):e0235518. PubMed ID: 32614928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
    Morimoto Y; Kishida T; Kotani SI; Takayama K; Mazda O
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):330-336. PubMed ID: 30446226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
    Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
    Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toll-like receptors 2, 4 and 7, interferon-gamma and interleukin 10, and programmed death ligand 1 transcripts in skin from dogs of different clinical stages of leishmaniosis.
    Ordeix L; Montserrat-Sangrà S; Martínez-Orellana P; Baxarias M; Solano-Gallego L
    Parasit Vectors; 2019 Dec; 12(1):575. PubMed ID: 31806038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
    Xiong H; Mittman S; Rodriguez R; Moskalenko M; Pacheco-Sanchez P; Yang Y; Nickles D; Cubas R
    Cancer Res; 2019 Apr; 79(7):1493-1506. PubMed ID: 30679180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms regulating PD-L1 expression on tumor and immune cells.
    Chen S; Crabill GA; Pritchard TS; McMiller TL; Wei P; Pardoll DM; Pan F; Topalian SL
    J Immunother Cancer; 2019 Nov; 7(1):305. PubMed ID: 31730010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
    Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
    Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.